Cargando…
Pre‐ and on‐treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non–small cell lung cancer
BACKGROUND: The survival outcomes of patients with advanced non–small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) are variable. This study investigated whether pre‐ and on‐treatment lactate dehydrogenase (LDH) could better prognosticate and select patients for ICI thera...
Autores principales: | Tjokrowidjaja, Angelina, Lord, Sarah J., John, Thomas, Lewis, Craig R., Kok, Peey‐Sei, Marschner, Ian C., Lee, Chee K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306897/ https://www.ncbi.nlm.nih.gov/pubmed/35090047 http://dx.doi.org/10.1002/cncr.34113 |
Ejemplares similares
-
Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis
por: Kok, Peey-Sei, et al.
Publicado: (2020) -
Prognostic relevance of lactate dehydrogenase in advanced pancreatic ductal adenocarcinoma patients
por: Xiao, Yuanyuan, et al.
Publicado: (2017) -
Pre-treatment serum alkaline phosphatase and lactate dehydrogenase as prognostic factors in triple negative breast cancer
por: Chen, Bo, et al.
Publicado: (2016) -
Dedifferentiated umbilical metastases from low grade endometrioid endometrial adenocarcinoma complicated by super-obesity: A case report
por: Odgers, Harrison, et al.
Publicado: (2023) -
Prognostic Value of Lactate Dehydrogenase in Second-Line Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma
por: Li, Yan, et al.
Publicado: (2022)